Treatment with bevacizumab is standard of care for recurrent high grade gliomas (HGGs) and the level of border distinctness is a major parameter to monitor the therapy. Previously, the level of border distinctness was defined qualitative. In this study, we calculated the distinctness of the fluid-attenuated inversion recovery (FLAIR) hyperintense border—edge contrast (EC)—and showed it improves the evaluation of response to bevacizumab in patients with HGG. We showed that after bevacizumab, lower EC of the FLAIR hyperintense region was associated with poorer survival among HGG patients. We developed a quantitative parameter to characterize the border of the tumor.
How to access this content:
For one year after publication, abstracts and videos are only open to registrants of this annual meeting. Registrants should use their existing login information. Non-registrant access can be purchased via the ISMRM E-Library.
After one year, current ISMRM & ISMRT members get free access to both the abstracts and videos. Non-members and non-registrants must purchase access via the ISMRM E-Library.
After two years, the meeting proceedings (abstracts) are opened to the public and require no login information. Videos remain behind password for access by members, registrants and E-Library customers.
Keywords